ArticleFrontiers in oncology2026
The impact of prevalent primary cancers in melanoma patients on survival.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The presence of prior malignancies at the time of cutaneous malignant melanoma diagnosis may be a critical determinant of patient survival. The present study evaluated the clinical and economic impact of prevalent cancers at the time of cutaneous melanoma diagnosis. Methods: This population-based retrospective cohort study included melanoma cases identified in the Italian Veneto Region Cancer Registry (RTV) in 2019 and 2021. Prevalent primary cancers that occurred within a five-year interval prior to melanoma diagnosis were identified from the RTV's multiple tumors dataset. Kaplan-Meier and Cox proportional hazards models were used to test the association between prevalent primary cancers and overall and melanoma-specific survival. Over three years, healthcare costs were analyzed from a health system perspective using administrative data. Results: Out of 2,978 melanoma patients, 134 (4.5%) had prevalent tumors. The most frequent additional cancer sites were prostate (30.2%), breast (10.8%), colon (7.9%), and kidney (7.2%). Prevalent malignancies were associated with older age, male sex, and greater comorbidity burden in melanoma patients. In univariate Cox regression analysis, prevalent tumors were associated with an increased risk of all-cause mortality (HR 2.23, 95% CI 1.59-3.15; p<0.001), whereas no significant association was observed with CM-specific mortality. After adjustment for prognostic factors, prevalent tumors remained independently associated with an increased risk of all-cause mortality (aHR 1.72, 95% CI 1.19-2.47; p=0.004), while the association with CM-specific mortality remained non-significant. Overall and melanoma-related costs were higher in melanoma patients with prevalent tumors (overall three-year average costs € 30,698.34 vs. € 17,471.23). Conclusions: The presence of prevalent tumors at the time of melanoma diagnosis influences the direct costs associated with healthcare. These findings highlight the significance of integrating multimorbidity considerations into the management and resource allocation in patients with cutaneous melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.